Bio-Techne (TECH) Long-Term Deferred Tax (2010 - 2025)
Bio-Techne's quarterly Long-Term Deferred Tax came in at $10.3 million in Q2 2025, up 1812.24% quarter-over-quarter from $539000.0 in Q1 2011.
Bio-Techne has reported Long-Term Deferred Tax for 3 years, with the latest figure at $10.3 million in Q2 2025.
- For the quarter ending Q2 2025, Long-Term Deferred Tax changed N/A year-over-year to $10.3 million; the trailing twelve-month figure through Jun 2025 stood at $10.3 million (changed N/A YoY), and the FY2025 full-year result was $10.3 million, changed N/A from the prior year.
- Long-Term Deferred Tax for Q2 2025 stood at $10.3 million, up from $539000.0 in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $10.3 million in Q2 2025, with the low at $10.3 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Bio-Techne | 7.92 Bn | 7.71 Bn | 208.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 10.31 Mn |
| Mar 31, 2011 | 539,000.00 |
| Dec 31, 2010 | 1.06 Mn |
| Sep 30, 2010 | 936,000.00 |
| Jun 30, 2010 | 1.01 Mn |